DavidRMandelMDFACR

Rheumatology • Solon, OH

Crystal Related, Osteoporosis & Bone Metabolism, Rheumatoid Arthritis & Related, Spondyloarthropathy

Physician

Join to view full profile

Dr. Mandel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mandel's full profile

Already have an account?

Office
5177 Lansdowne Drive
Solon, OH 44139
Phone+1 216-299-0059

Summary

David Mandel, M.D. retired in February ,2024 from the practice of adult rheumatology after 42 years in Northeast Ohio. He continues his passion to teach medical students and residents as well as podiatry and physician assistant students at many institutions. He remains active in the Ohio Association of Rheumatology which he was a cofounder and volunteers for other organizations.
He looks forward to this next chapter!

Education & Training

Cleveland Clinic FoundationFellowship, Rheumatology, 1980 - 1982
Akron General Medical Center/NEOMEDResidency, Internal Medicine, 1977 - 1980
University of Cincinnati College of MedicineClass of 1977

Certifications & Licensure

OH State Medical License 1978 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

Fellow (FACR) American College of Rheumatology

Clinical Trials

Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout Start of enrollment: 2006 May 01
Completed
Phase 3
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder Start of enrollment: 2011 Nov 01
Completed
Phase 2
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen Start of enrollment: 2006 Oct 04
Completed
Phase 4
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT) Start of enrollment: 2007 May 15
Terminated
Phase 3
Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease Start of enrollment: 2007 Oct 01
Completed
Phase 3
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis Start of enrollment: 2007 Feb 05
Completed
Phase 3
Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip Start of enrollment: 2009 Feb 12
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

225 citations
Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial
David R Mandel, Katy Eichas, Judith Holmes
BMC Complementary and Alternative Medicine. 2010-01-12
91 citations
A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis
Alan K. Matsumoto, Augustin Melian, David R. Mandel, Harris H. McIlwain, David G. Borenstein
The Journal of Rheumatology. 2002-08-01
13 citations
Streptobacillary fever. An unusual cause of infectious arthritis.
David R. Mandel
Cleveland Clinic Quarterly. 1985-06-20

Professional Memberships

American College of Rheumatology - ACR
Fellow